Lates News
The US FDA has approved Merck's blockbuster cancer therapy Keytruda in subcutaneous injection form. Analysts say this marks a significant change in the dosing method of this globally top-selling cancer immunotherapy, with the potential to improve patient experience and clinical efficiency. This move is also seen as a strategic component of Merck's defense of Keytruda's market share as competition from biosimilars intensifies.
Latest